Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse.

摘要: The incidence and clinical meaning of elevated alanine aminotransferase (ALT) in chronic hepatitis C patients who are virus (HCV)-RNA negative during pegylated interferon (PEG-IFN) ribavirin therapy have not been completely characterized. In this study our aim was to assess the incidence, pattern, predictive factors, ALT a cohort 173 obtained viral clearance either PEG-IFNα2a or α2b weight-based therapy. Patients were defined sustained responders (SVRs) relapser (RRs) on basis serum HCV-RNA result at 24-week follow-up. SVR RR 141 (58%) 32 (13%), respectively. Among patients, 57 (33%) had undetectable least one evaluation (weeks 2, 4, 12, 24 all genotypes, week 48 HCV genotype 1 4 alone), phenomenon differently distributed between SVRs RRs. No pretreatment demographic (age, gender), (ALT levels, histological grade stage, body mass index) (load, genotype) parameter associated with phenomenon. levels type PEG-IFN dose. Elevated showed different longitudinal occurring more frequently 12 end treatment as compared (90% versus 9%, P = 0.000001). Conclusion: occurrence HCV-RNA-negative is fairly frequent unpredictable Although elevation per se greater risk relapse, its later phases common relapsing patients. (HEPATOLOGY 2009.)